Dataset related to article "Biochemical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors by Cardiovascular Risk Profile and Volume Status in a Real-World Diabetic Population "

This record contains raw data related to article “Biochemical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors by Cardiovascular Risk Profile and Volume Status in a Real-World Diabetic Population" Abstract Despite large-scale randomized clinical trials (RCTs) highlighting a consistent prognostic benefit of sodium-glucose cotransporter 2 inhibitors (SGLT2is) both in diabetic patients at high cardiovascular risk and in those with heart failure, there is relative paucity of data on their biochemical effects in a real-world setting. We performed a retrospective analysis on consecutive diabetic patients who were prescribed a SGLT2i in a tertiary referral center and completed at least 1 year of treatment. Changes in glycated hemoglobin, weight, and hematocrit were compared across 2 cardiovascular risk categories, defined through the inclusion criteria of 3 large RCTs. Of the 459 patients screened, 312 completed 1 year of treatment (68.0%), 92 interrupted the treatment prematurely (20.0%), and 55 were lost to follow-up (12.0%). The most common cause of drug discontinuation was genital or urinary tract infections (9.4%). At 1 year, reduction in glycated hemoglobin concentration (-0.7 ± 1.5%, P &lt; 0.001) and body weight (2.4 ± 4.6 kg, P &lt; 0.001) was comparable between patients at high versus low cardiovascular risk, while hematocrit increase (2.3 ± 3.3%, P &lt; 0.001) was more marked in patients with high cardiovascular risk and low baseline hematocrit. In a real-world population of diabetic patients, SGLT2is were well-tolerated at 1 year and led to improved glycemic control and weight loss. Hematocrit increase was more consistent in patients with high cardiovascular risk and signs of fluid overload, indicating euvolemic restoration as a potential cardioprotective mechanism mediated by these compounds.本数据集包含与论文《真实世界糖尿病人群中基于心血管风险分层与容量状态的钠-葡萄糖协同转运蛋白2抑制剂（sodium-glucose cotransporter 2 inhibitors, SGLT2is）生化疗效》相关的原始数据。 摘要：尽管多项大规模随机对照试验（randomized clinical trials, RCTs）已证实钠-葡萄糖协同转运蛋白2抑制剂（SGLT2is）对高心血管风险糖尿病患者及心力衰竭患者均具有一致的预后获益，但目前关于其在真实世界场景下的生化效应的相关数据仍相对匮乏。本研究针对某三级转诊中心中开具了SGLT2i处方且完成至少1年治疗的连续性糖尿病患者开展了回顾性分析。依据3项大型RCT的纳入标准划分2类心血管风险分层，对比不同分层患者的糖化血红蛋白（glycated hemoglobin）、体重及红细胞比容（hematocrit）的变化情况。纳入筛查的459例患者中，312例完成了1年治疗（占比68.0%），92例提前终止治疗（占比20.0%），55例失访（占比12.0%）。药物终止治疗最常见的诱因为生殖道或泌尿道感染（占比9.4%）。治疗1年后，高心血管风险与低心血管风险患者的糖化血红蛋白浓度（-0.7±1.5%，P<0.001）及体重（2.4±4.6kg，P<0.001）降幅均无显著差异；而高心血管风险且基线红细胞比容偏低的患者，其红细胞比容升高幅度（2.3±3.3%，P<0.001）更为显著。在真实世界糖尿病患者人群中，SGLT2is在1年治疗期间耐受性良好，可改善血糖控制并减轻体重。高心血管风险且存在液体超负荷征象的患者，其红细胞比容升高更为显著，提示容量稳态恢复可能是此类药物介导的潜在心脏保护机制。